One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma - The New England Journal of Medicine
NEJM • 2/19/2026
Summary
The New England Journal of Medicine reports on a pivotal trial that establishes one trial as the new default option for FDA approval, effectively ending the two-trial dogma.
Advertisement
Lindy Score Breakdown (V4.2)
59d
Age
1
Sources
from cluster
1413
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1413/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1413/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 59 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Pharmalittle: We’re reading about Lilly weight loss pill trial results, slashed U.K. clinical trial times, and more
Stat News • 1 day ago
STAT+: Roche to launch another Elevidys trial, with eyes on European approval
Stat News • 2 days ago
STAT+: Up and down the ladder: The latest comings and goings
Stat News • 1 day ago
The deadly consequences of ICE detention
Stat News • 1 day ago
STAT+: Medicare may nix breakthrough device payment pathway
Stat News • 2 days ago
STAT+: RFK Jr. begins his testimony marathon
Stat News • 2 days ago
STAT+: 7 key issues we’re watching as RFK Jr. faces a Congressional gauntlet
Stat News • 2 days ago
STAT+: FDA eyes expanding testosterone therapy for libido
Stat News • 1 day ago
STAT+: Kennedy focuses on affordability, combating fraud in Capitol Hill hearings
Stat News • 2 days ago
Optimism for Trump’s CDC pick is tempered by questions about RFK Jr.’s role
Stat News • Today